OraSure Technologies, Inc. (OSUR)

Market Cap	207.38M -12.3%
Revenue (ttm)	115.02M -38.1%
Net Income	-68.73M
EPS	-0.94
Shares Out	69.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	481,546
Open	3.030
Previous Close	3.050
Day's Range	2.930 - 3.050
52-Week Range	2.080 - 3.820
Beta	0.85
Analysts	Hold
Price Target	3.00 (0.0%)
Earnings Date	May 6, 2026

About OSUR

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid tes...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Nov 12, 1986
• Employees: 500
• Stock Exchange: NASDAQ
• Ticker Symbol: OSUR
• Website: https://www.orasure.com

Financial Performance

In 2025, OraSure Technologies's revenue was $115.02 million, a decrease of -38.10% compared to the previous year's $185.83 million. Losses were -$68.73 million, 252.5% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for OSUR stock is "Hold." The 12-month stock price target is $3.0, which is no change of 0.00% from the latest price.

Price Target

$3.0

Analyst Consensus: Hold